Structure of acetylcholinesterase complexed with E2020 (Aricept®): implications for the design of new anti-Alzheimer drugs

Drachman, 1974, Human memory and the cholinergic system, Arch. Neurol, 30, 113, 10.1001/archneur.1974.00490320001001

Bowen, 1983, Biochemical assessment of serotonergic and cholinergic dysfunction and cerebral atrophy in Alzheimer's disease, J. Neurochem, 41, 266, 10.1111/j.1471-4159.1983.tb11838.x

Bartus, 1982, The cholinergic hypothesis of geriatric memory dysfunction, Science, 217, 408, 10.1126/science.7046051

Dunnett, 1993, Role of forebrain cholinergic systems in learning and memory: relevance to the cognitive deficits of aging and Alzheimer's dementia, Prog. Brain Res, 98, 413, 10.1016/S0079-6123(08)62425-5

Weinstock, 1997, Possible role of the cholinergic system and disease models, J. Neural Transm. Suppl, 49, 93

Becker, 1988, Potential pharmacotherapy of Alzheimer's disease. A comparison of various forms of physostigmine administration, Acta Neurol. Scand. Suppl, 116, 19, 10.1111/j.1600-0404.1988.tb07983.x

Zhang, 1991, Drug evaluation of huperzine A in the treatment of senile memory disorders, Acta Pharm. Sinica, 12, 250

Weinstock, 1994, Pharmacological evaluation of phenyl-carbamates as CNS-selective acetylcholinesterase inhibitors, J. Neural Transm. Suppl, 43, 219

Knopman, 1998, Metrifonate for Alzheimer's disease: Is the next cholinesterase inhibitor better?, Neurology, 50, 1203, 10.1212/WNL.50.5.1203

Inestrosa, 1996, Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme, Neuron, 16, 881, 10.1016/S0896-6273(00)80108-7

Reyes, 1997, A monoclonal antibody against acetylcholinesterase inhibits the formation of amyloid fibrils induced by the enzyme, Biochem. Biophys. Res. Commun, 232, 652, 10.1006/bbrc.1997.6357

Davis, 1995, Tacrine, Lancet, 345, 625, 10.1016/S0140-6736(95)90526-X

Nightingale, 1997, Donepezil approved for treatment of Alzheimer's disease, JAMA, 277, 10, 10.1001/jama.1997.03540250018010

Kawakami, 1996, The rationale for E2020 as a potent acetylcholinesterase inhibitor, Bioorg. Med. Chem, 4, 1429, 10.1016/0968-0896(96)00137-X

Cardozo, 1992, QSAR analyses of the substituted indanone and benzylpiperidine rings of a series of indanone-benzylpiperidine inhibitors of acetylcholinesterase, J. Med. Chem, 35, 584, 10.1021/jm00081a022

Cardozo, 1992, Conformational analyses and molecular-shape comparisons of a series of indanone-benzylpiperidine inhibitors of acetylcholinesterase, J. Med. Chem, 35, 590, 10.1021/jm00081a023

Sussman, 1991, Atomic structure of acetylcholinesterase from Torpedo californica: a prototypic acetylcholine-binding protein, Science, 253, 872, 10.1126/science.1678899

Rupniak, 1997, Enhanced performance of spatial and visual recognition memory tasks by the selective acetylcholinesterase inhibitor E2020 in rhesus monkeys, 131

Galli, 1994, Acetylcholinesterase protection and the anti-diisopropylfluorophosphate efficacy of E2020, Eur. J. Pharmacol, 270, 189

Thomsen, 1990, Selective inhibition of human acetylcholinesterase by galanthamine in vitro and in vivo, Life Sci, 46, 1553, 10.1016/0024-3205(90)90429-U

Loewenstein, 1993, Chimeric human cholinesterase. Identification of interaction sites responsible for recognition of acetyl- or butyrylcholinesterase-specific ligands, J. Mol. Biol, 234, 289, 10.1006/jmbi.1993.1584

Sugimoto, 1995, Synthesis and structure-activity-relationships of acetylcholinesterase inhibitors – 1-Benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl]piperidine hydrochloride and related compounds, J. Med. Chem, 38, 4821, 10.1021/jm00024a009

Cheng, 1996, Huperzine A, a novel promising acetylcholinesterase inhibitor, Neuroreport, 8, 97, 10.1097/00001756-199612200-00020

Villalobos, 1995, 5,7-dihydro-3-[2-[1-(phenylmethyl)-4-piperidinyl]ethyl]-6H- pyrrolo[3,2-f]-1,2-benzisoxazol-6-one: a potent and centrally-selective inhibitor of acetylcholinesterase with an improved margin of safety, J. Med. Chem, 38, 2802, 10.1021/jm00015a002

Pang, 1994, Prediction of the binding site of 1-benzyl-4-[(5,6-dimethoxy-1-indanon-2-yl)methyl]piperidine in acetylcholinesterase by docking studies with the SYSDOC program, J. Comput. Aided Mol. Des, 8, 683, 10.1007/BF00124015

Harel, 1992, Conversion of acetylcholinesterase to butyrylcholinesterase: modeling and mutagenesis, Proc. Natl Acad. Sci. USA, 89, 10827, 10.1073/pnas.89.22.10827

Schumacher, 1986, Primary structure of Torpedo californica acetylcholinesterase deduced from its cDNA sequence, Nature, 319, 407, 10.1038/319407a0

Harel, 1993, Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase, Proc. Natl Acad. Sci. USA, 90, 9031, 10.1073/pnas.90.19.9031

Harel, 1996, The X-ray structure of a transition state analog complex reveals the molecular origins of the catalytic power and substrate specificity of acetylcholinesterase, J. Am. Chem. Soc, 118, 2340, 10.1021/ja952232h

Levitt, 1988, Aromatic rings act as hydrogen bond acceptors, J. Mol. Biol, 201, 751, 10.1016/0022-2836(88)90471-8

Burley, 1986, Amino-aromatic interactions in proteins, FEBS Lett, 203, 139, 10.1016/0014-5793(86)80730-X

Inoue, 1996, The simulated binding of (+/-)-2,3-dihydro-5,6-dimethoxy-2-[(1-(phenylmethyl)-4-piperidinyl)methyl]-1H-inden-1-one hydrochloride (E2020) and related inhibitors to free and acylated acetylcholinesterases and corresponding structure-activity analyses, J. Med. Chem, 39, 4460, 10.1021/jm950596e

Verdonk, 1993, Stereochemistry of charged nitrogen-aromatic interactions and its involvement in ligand-receptor binding, J. Comput. Aided Mol. Des, 7, 173, 10.1007/BF00126443

Dougherty, 1996, Cation-π interactions in chemistry and biology: A new view of benzene, Phe, Tyr, and Trp, Science, 271, 163, 10.1126/science.271.5246.163

1993

Raves, 1997, Structure of acetylcholinesterase complexed with the nootropic alkaloid, (-)-huperzine A, Nat. Struct. Biol, 4, 57, 10.1038/nsb0197-57

Shafferman, 1992, Substrate inhibition of acetylcholinesterase: residues affecting signal transduction from the surface to the catalytic center, EMBO J, 11, 3561, 10.1002/j.1460-2075.1992.tb05439.x

Ordentlich, 1993, Dissection of the human acetylcholinesterase active center determinants of substrate specificity. Identification of residues constituting the anionic site, the hydrophobic site, and the acyl pocket, J. Biol. Chem, 268, 17083, 10.1016/S0021-9258(19)85305-X

Radic, 1993, Three distinct domains in the cholinesterase molecule confer selectivity for acetyl- and butyrylcholinesterase inhibitors, Biochemistry, 32, 12074, 10.1021/bi00096a018

Antosiewicz, 1996, Acetylcholinesterase: role of the enzyme's charge distribution in steering charged ligands toward the active site, Biopolymers, 39, 85, 10.1002/(SICI)1097-0282(199607)39:1<85::AID-BIP9>3.3.CO;2-K

Zhou, 1998, Conformation gating as a mechanism for enzyme specificity, Proc. Natl Acad. Sci. USA, 95, 9280, 10.1073/pnas.95.16.9280

Shah, 1993, Clinical pharmacokinetics: current requirements and future perspectives from a regulatory point of view, Xenobiotica, 23, 1159, 10.3109/00498259309059432

Nation, 1989, Enantioselective drug analysis: problems and resolutions, Clin. Exp. Pharmacol. Physiol, 16, 471, 10.1111/j.1440-1681.1989.tb01590.x

Barnard, 1974, Neuromuscular transmission – enzymatic destruction of acetylcholine, 201

Baron, 1998, Kinetic and X-ray crystallographic studies of the binding of ENA-713 to Torpedo californica acetylcholinesterase (TcAChE), 373

Bourne, 1998, Crystal structure of mouse acetylcholinesterse, 315

Kryger, 1998, 3D structure of a complex of human recombinant acetylcholinesterase with fasciculin-II at 2.7 Å resolution, 323

Greenblatt, 1998, Crystal structures of complexes of E2020 related compounds with Torpedo acetylcholinesterase, 371

Kryger, 1998, Structural studies on human and insect acetylcholinesterase

Hope, 1988, Cryocrystallography of biological macromolecules: a generally applicable method, Acta Crystallogr. B, 44, 22, 10.1107/S0108768187008632

Ravelli, 1997, STRATEGY: a program to optimize the starting spindle angle and scan range for X-ray data collection, J. Appl. Crystallogr, 30, 551, 10.1107/S0021889897003543

Otwinowski, 1993, Oscillation data reduction program, 56

Brünger, 1987, Crystallographic R factor refinement by molecular dynamics, Science, 235, 458, 10.1126/science.235.4787.458

Jones, 1991, Improved methods for the building of protein models in electron density maps and the location of errors in these models, 413

Kleywegt, 1996, Efficient rebuilding of protein structures, Acta Crystallogr. D, 52, 829, 10.1107/S0907444996001783

Laskowski, 1993, PROCHECK: a program to check the stereochemical quality of protein structures, J. Appl. Crystallogr, 26, 283, 10.1107/S0021889892009944

Vriend, 1990, WHAT IF: a molecular modelling and drug design program, J. Mol. Graph, 8, 52, 10.1016/0263-7855(90)80070-V

Laskowski, 1995, SURFNET: a program for visualizing molecular surfaces, cavities and intermolecular interactions, J. Mol. Graph, 13, 323, 10.1016/0263-7855(95)00073-9